Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2021

Linares JF, Zhang X, Martinez-Ordoñez A, Duran A, Kinoshita H, Kasashima H, et al. PKCλ/ι inhibition activates an ULK2-mediated interferon response to repress tumorigenesis. Mol Cell. 2021.

Miltiadous O, Petrova-Drus K, Kaicker S, Mathew S, Kluk M, Geyer JT, et al. Successful treatment and integrated genomic analysis of an infant with FIP1L1-RARA fusion-associated myeloid neoplasm. Blood Adv. 2021.

Liu D, Augello MA, Grbesa I, Prandi D, Liu Y, Shoag JE, et al. Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancer. J Clin Invest. 2021;131(10).

Fine SW, Trpkov K, Amin MB, Algaba F, Aron M, Baydar DE, et al. Practice patterns related to prostate cancer grading: results of a 2019 Genitourinary Pathology Society clinician survey. Urol Oncol. 2021;39(5):295.e1-295.e8.

Cheng S, Zhang W, Inghirami G, Tam W. Mutation analysis links angioimmunoblastic T-cell lymphoma to clonal hematopoiesis and smoking. Elife. 2021;10.

Imada EL, Strianese D, Edward DP, alThaqib R, Price A, Arnold A, et al. RNA-sequencing highlights differential regulated pathways involved in cell cycle and inflammation in orbitofacial neurofibromas. Brain Pathol. 2021:e13007.

Showers CR, Nuovo GJ, Lakhanpal A, Siegel CH, Aizer J, Elreda L, et al. A Covid-19 Patient with Complement-Mediated Coagulopathy and Severe Thrombosis. Pathobiology. 2021;88(1):28-36.

Larose H, Prokoph N, Matthews JD, Schlederer M, Högler S, Alsulami AF, et al. Whole Exome Sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target. Haematologica. 2021;106(6):1693-1704.

Park J, Foox J, Hether T, Danko D, Warren S, Kim Y, et al. Systemic Tissue and Cellular Disruption from SARS-CoV-2 Infection revealed in COVID-19 Autopsies and Spatial Omics Tissue Maps. bioRxiv. 2021.

Lopez A, Patel S, Geyer JT, Racchumi J, Chadburn A, Simonson P, et al. Comparison of Multiple Clinical Testing Modalities for Assessment of NPM1-Mutant AML. Front Oncol. 2021;11:701318.